The 10 Latest Novel Drug Approvals

Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.

This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.

The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.

Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.

Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.

Pharmacists expand access with no-appointment care but face state laws limiting test-to-treat for COVID-19 and flu, fueling calls for advocacy.

AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.

Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.